Fig. 2

Plots of a) eGFR and b) TKV over time for individual patients in Cohort 1. Patients are designated by color as Mayo risk class 1B–1E. a eGFR collected during the first week of treatment and first week posttreatment was removed. b Data points shown in the figure prior to time 0 (last dose of tolvaptan) were on-treatment assessments. Baseline assessments that were prior to the first dose of tolvaptan are not shown in the figure. eGFR, estimated glomerular filtration rate; TKV, total kidney volume